Cargando…

Nanobody-Enhanced Targeting of AAV Gene Therapy Vectors

A limiting factor for the use of adeno-associated viruses (AAVs) as vectors in gene therapy is the broad tropism of AAV serotypes, i.e., the parallel infection of several cell types. Nanobodies are single immunoglobulin variable domains from heavy chain antibodies that naturally occur in camelids. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eichhoff, Anna Marei, Börner, Kathleen, Albrecht, Birte, Schäfer, Waldemar, Baum, Natalie, Haag, Friedrich, Körbelin, Jakob, Trepel, Martin, Braren, Ingke, Grimm, Dirk, Adriouch, Sahil, Koch-Nolte, Friedrich
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819893/ https://www.ncbi.nlm.nih.gov/pubmed/31687421 http://dx.doi.org/10.1016/j.omtm.2019.09.003

Ejemplares similares

Evaluation of P2X7 Receptor Function in Tumor Contexts Using rAAV Vector and Nanobodies (AAVnano)
por: Demeules, Mélanie, et al.
Publicado: (2020)

Effective targeting of microglial P2X7 following intracerebroventricular delivery of nanobodies and nanobody-encoding AAVs
por: Pinto-Espinoza, Carolina, et al.
Publicado: (2022)

Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors
por: Hambach, Julia, et al.
Publicado: (2022)

A Methodological Approach Using rAAV Vectors Encoding Nanobody-Based Biologics to Evaluate ARTC2.2 and P2X7 In Vivo
por: Gondé, Henri, et al.
Publicado: (2021)

P2X7 on Mouse T Cells: One Channel, Many Functions
por: Rissiek, Björn, et al.
Publicado: (2015)

Evaluation of nanobody-based biologics targeting purinergic checkpoints in tumor models in vivo
por: Demeules, Mélanie, et al.
Publicado: (2022)

A cDNA Immunization Strategy to Generate Nanobodies against Membrane Proteins in Native Conformation
por: Eden, Thomas, et al.
Publicado: (2018)

Nanobody-Based Biologics for Modulating Purinergic Signaling in Inflammation and Immunity
por: Menzel, Stephan, et al.
Publicado: (2018)

Selection of Nanobodies that Block the Enzymatic and Cytotoxic Activities of the Binary Clostridium Difficile Toxin CDT
por: Unger, Mandy, et al.
Publicado: (2015)

T Cells of Different Developmental Stages Differ in Sensitivity to Apoptosis Induced by Extracellular NAD
por: Haag, Friedrich, et al.
Publicado: (2002)

Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics
por: Bannas, Peter, et al.
Publicado: (2017)

Activation of the P2X7 ion channel by soluble and covalently bound ligands
por: Schwarz, Nicole, et al.
Publicado: (2009)

Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy
por: Bannas, Peter, et al.
Publicado: (2015)

Daratumumab and Nanobody-Based Heavy Chain Antibodies Inhibit the ADPR Cyclase but not the NAD(+) Hydrolase Activity of CD38-Expressing Multiple Myeloma Cells
por: Baum, Natalie, et al.
Publicado: (2020)

Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs)
por: Hambach, Julia, et al.
Publicado: (2020)

Monitoring the expression of purinoceptors and nucleotide-metabolizing ecto-enzymes with antibodies directed against proteins in native conformation
por: Möller, Sina, et al.
Publicado: (2007)

ASC nanobodies to counteract the consequences of inflammasome activation
por: Adriouch, Sahil, et al.
Publicado: (2022)

Extracellular NAD and ATP: Partners in immune cell modulation
por: Haag, Friedrich, et al.
Publicado: (2007)

Alternative Splicing of the N-Terminal Cytosolic and Transmembrane Domains of P2X7 Controls Gating of the Ion Channel by ADP-Ribosylation
por: Schwarz, Nicole, et al.
Publicado: (2012)

Extracellular NAD(+) shapes the Foxp3(+) regulatory T cell compartment through the ART2–P2X7 pathway
por: Hubert, Sandra, et al.
Publicado: (2010)

Nanobodies: new avenue to treat kidney disease
por: Wanner, Nicola, et al.
Publicado: (2021)

Nanobodies as modulators of inflammation: potential applications for acute brain injury
por: Rissiek, Björn, et al.
Publicado: (2014)

Peptide Ligands Incorporated into the Threefold Spike Capsid Domain to Re-Direct Gene Transduction of AAV8 and AAV9 In Vivo
por: Michelfelder, Stefan, et al.
Publicado: (2011)

Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies
por: Schriewer, Levin, et al.
Publicado: (2020)

Current Approaches and Future Perspectives for Nanobodies in Stroke Diagnostic and Therapy
por: Jank, Larissa, et al.
Publicado: (2019)

Tuning IL-2 signaling by ADP-ribosylation of CD25
por: Teege, Sophie, et al.
Publicado: (2015)

Origin, distribution, and function of three frequent coding polymorphisms in the gene for the human P2X7 ion channel
por: Schäfer, Waldemar, et al.
Publicado: (2022)

Ecto-ADP-ribosyltransferase ARTC2.1 functionally modulates FcγR1 and FcγR2B on murine microglia
por: Rissiek, Björn, et al.
Publicado: (2017)

CD83 Modulates B Cell Function In Vitro: Increased IL-10 and Reduced Ig Secretion by CD83Tg B Cells
por: Kretschmer, Birte, et al.
Publicado: (2007)

Vascular Endothelial Cells: Heterogeneity and Targeting Approaches
por: Hennigs, Jan K., et al.
Publicado: (2021)

ADP-ribosylation of arginine
por: Laing, Sabrina, et al.
Publicado: (2010)

Improved targeting of human CD4(+) T cells by nanobody-modified AAV2 gene therapy vectors
por: Hamann, Martin V., et al.
Publicado: (2021)

CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells
por: Schütze, Kerstin, et al.
Publicado: (2018)

Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells
por: Hambach, Julia, et al.
Publicado: (2022)

Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38(+) tumors in mouse models in vivo
por: Fumey, William, et al.
Publicado: (2017)

Immuno-targeting the multifunctional CD38 using nanobody
por: Li, Ting, et al.
Publicado: (2016)

CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy
por: Pape, Luca Julius, et al.
Publicado: (2022)

Improved Immunological Tolerance Following Combination Therapy with CTLA-4/Ig and AAV-Mediated PD-L1/2 Muscle Gene Transfer
por: Adriouch, Sahil, et al.
Publicado: (2011)

Generation and Characterization of Specific Monoclonal Antibodies and Nanobodies Directed Against the ATP-Gated Channel P2X4
por: Bergmann, Philine, et al.
Publicado: (2019)

Single domain antibodies: promising experimental and therapeutic tools in infection and immunity
por: Wesolowski, Janusz, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_o88rfh1ue27j72tdnpsnbblcbg